Furthermore, our results suggest that ACTN3 R577X genotype will contribute to the clinical variability in patients with partial or mild androgen insensitivity syndrome and may also affect the health outcomes and treatment response of patients with prostate cancer who undergo ADTs (77). This evidence concerns the gene ACTN3 and prostate cancer.